Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)
NCT ID: NCT01947309
Last Updated: 2017-01-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
176 participants
OBSERVATIONAL
2013-11-30
2016-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Non-interventional, Observational Post-marketing Registry of Patients Treated With Revlimid (Lenalidomide) in Taiwan
NCT01752075
Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma
NCT01593410
A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant
NCT03106324
A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use
NCT02922543
Lenalidomide Maintenance Therapy for Multiple Myeloma
NCT01675141
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The registry will capture data from 600 patients being prescribed REVLIMID in specified hospitals and all patients will be followed in the registry for two years after enrollment of the last patient.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Multiple Myeloma Patients Treated with Revlimid (lenalidomide)
Single Cohort of Multiple Myeloma Patients Treated with Revlimid
Revlimid (lenalidomide)
Revlimid (lenalidomide) as prescribed in usual clinical practice
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Revlimid (lenalidomide)
Revlimid (lenalidomide) as prescribed in usual clinical practice
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Celgene
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yu (Flora) Yao, MD
Role: STUDY_DIRECTOR
Celgene Pharmaceutical (Shanghai) Co. Ltd.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking Chao-Yang Hospital
Beijing, , China
Peking University People's Hospital
Beijing, , China
People's Liberation Army Hospital 307
Beijing, , China
Beijing Hospital
Beijing, , China
The Fisrt Hospital Of Jilin University
Changchun, , China
Xiangya Hospital Central-South University
Changsha, , China
Xinqiao Hospital, 3rd Military Medical University
Chongqing, , China
NanFang Hospital of China Southern Medical University
Guangzhou, , China
The First Affliated Hospital of Anhui Medical University
Hefei, , China
Qilu Hospital of Shandong University
Jinan, , China
The Affiliated Hospital of Mecical College Qingdao University
Qingdao, , China
Shanghai Changzhen Hospital
Shanghai, , China
The Second Affiliated Hospital Of China Medical University
Shenyang, , China
The First Affiliated Hospital of Suzhou University
Suzhou, , China
People's Hospital of Xinjiang Uygur Autonomous Region
Ürümqi, , China
Wuhan Union Hospital of Tongji Medical College of Huazhong University of Science & Technology
Wuhan, , China
Tongji Medical College Huazhong University of Science & Technology
Wuhan, , China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Wang GM, Yang GZ, Huang ZX, Zhong YP, Jin FY, Liao AJ, Wang XM, Fu ZZ, Liu H, Li XL, Zhou JF, Zhang X, Hu Y, Meng FY, Huang XJ, Chen WM, Lu J. [A prospective multi-center trial of non-interventional and observational study of lenalidomide in Chinese patients with multiple myeloma]. Zhonghua Nei Ke Za Zhi. 2017 Jul 1;56(7):500-506. doi: 10.3760/cma.j.issn.0578-1426.2017.07.006. Chinese.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIPMS-RV-CN-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.